Page 129 - 《中国药房》2025年18期
P. 129

实验,临床研究较少,对临床治疗的指导有限。因此,未                               mammary  epithelial  cells  by  inhibiting  NF- κB-mediated
          来既要加强基础研究,也要开展更多标准化的临床研                                 NLRP3  inflammasome  activation  via  upregulating  the
          究,以完善临床数据,促进基础研究成果的转化,更好地                               Nrf2  signaling  pathway[J].  Int  J  Biol  Macromol,2025,
          服务于临床。(3)相关研究多集中于基因及蛋白等分子层                              301:140133.
                                                             [10]  HENEDAK  N T,EL-ABHAR  H  S,SOUBH A A,et  al.
          面,聚焦的靶点较少,且缺乏具体的有效性验证研究。因
                                                                  NLRP3 inflammasome:a central player in renal patholo‐
          此,未来可以借助生物信息学、机器学习、蛋白质及代谢
                                                                  gies and nephropathy[J]. Life Sci,2024,351:122813.
          组学等技术,发掘更多潜在的中药有效成分及作用靶点,
                                                             [11]  ISLAMUDDIN  M,QIN  X  B.  Renal  macrophages  and
          并系统开展安全性与有效性评价,为RF的治疗提供更加
                                                                  NLRP3 inflammasomes in kidney diseases and therapeu‐
          多元化的策略。(4)常用的动物和细胞实验模型多是基于
                                                                  tics[J]. Cell Death Discov,2024,10:229.
          西医学构建获得,难以体现中医证候,与中医学理论的结                          [12]  CHEN Z,CHEN R,WANG J M,et al. Ligusticum cyclo‐
          合度较差。因此,未来应开发更多基于中医理论构建的                                prolactam ameliorates hyperuricemic nephropathy through
          病证结合模型,更准确地反映中医药防治RF的可靠性。                               inhibition of TLR4/NF-κB signaling[J]. J Nutr Biochem,
          参考文献                                                    2025,139:109864.
          [ 1 ]  GBD  2021  Diseases  and  Injuries  Collaborators.  Global     [13]  SU J Q,WU X Q,WANG Q,et al. The microbial metabo‐
              incidence,prevalence,years lived with disability(YLDs),  lite  trimethylamine  N-oxide  and  the  kidney  diseases[J].
              disability-adjusted  life-years(DALYs),and  healthy  life   Front Cell Infect Microbiol,2025,15:1488264.
              expectancy(HALE) for 371 diseases and injuries in 204   [14]  KONG Y B,WU D Y,WANG G X,et al. Tetrabromobi‐
              countries  and  territories  and  811  subnational  locations,  sphenol S(TBBPS) exposure induced the testicular aging
              1990-2021:a systematic analysis for the Global Burden of   through  NLRP3-mediated  inflammatory  signaling  path‐
              Disease Study 2021[J]. Lancet,2024,403(10440):2133-  way in vitro and in vivo[J]. Int Immunopharmacol,2025,
              2161.                                               152:114476.
          [ 2 ]  YUAN  Q,TANG  B,ZHANG  C.  Signaling  pathways  of   [15]  FRĄK W,DĄBEK B,BALCERCZYK-LIS M,et al. Role
              chronic  kidney  diseases,implications  for  therapeutics[J].   of  uremic  toxins,oxidative  stress,and  renal  fibrosis  in
              Signal Transduct Target Ther,2022,7(1):182.         chronic kidney disease[J]. Antioxidants(Basel),2024,13
          [ 3 ]  ARTLETT  C  M.  The  mechanism  and  regulation  of  the   (6):687.
              NLRP3  inflammasome  during  fibrosis[J].  Biomolecules,  [16]  LI J L,LIN Q S,SHAO X H,et al. HIF1α-BNIP3-me-
              2022,12(5):634.                                     diated mitophagy protects against renal fibrosis by decrea-
          [ 4 ]  HU J J,PANG X Y,LIANG X,et al. Raspberry amelio‐  sing ROS and inhibiting activation of the NLRP3 inflam‐
              rates renal fibrosis in rats with chronic kidney disease via   masome[J]. Cell Death Dis,2023,14(3):200.
              the  PI3K/Akt  pathway[J].  Phytomedicine,2025,140:  [17]  WANG Y L,SONG D X,TANG L. Mitophagy,inflamma‐
              156589.                                             somes and their interaction in kidney diseases:a compre‐
          [ 5 ]  WANG  X  Y,ZHAO  S  H,WANG  A  N,et  al.  Meta-  hensive review of experimental studies[J]. J Inflamm Res,
              analysis  of  traditional  Chinese  medicine  on  chronic  kid‐  2023,16:1457-1469.
              ney disease[J]. Expert Rev Pharmacoecon Outcomes Res,  [18]  SI Y C,LIU L L,CHENG J,et al. Oral hydrogen-rich wa‐
              2024,24(3):353-359.                                 ter  alleviates  oxalate-induced  kidney  injury  by  suppres-
          [ 6 ]  ZHANG Y,CHE N,WANG B,et al. 1,2,4-trimethoxy‐    sing oxidative stress,inflammation,and fibrosis[J]. Front
              benzene  ameliorates  depression-like  behaviors  by  inhibi-  Med,2021,8:713536.
              ting the activation of NLRP3 inflammasome[J]. Int Immu‐  [19]  WANG Y F,YOU Y K,GUO J B,et al. C-reactive protein
              nopharmacol,2025,151:114361.                        promotes  diabetic  kidney  disease  via  Smad3-mediated
          [ 7 ]  MA Q. Pharmacological inhibition of the NLRP3 inflam‐  NLRP3  inflammasome  activation[J].  Mol Ther,2025,33
              masome:structure,molecular  activation,and  inhibitor-  (1):263-278.
              NLRP3  interaction[J].  Pharmacol  Rev,2023,75(3):  [20]  晏子友,杨芸琪,沈金峰,等. 肾衰方及其拆方对肾间质
              487-520.                                            纤维化 VEGF、VEGFR2、α-SMA 的影响[J]. 中华中医药
          [ 8 ]  REN D,YE X O,CHEN R M,et al. Activation and eva‐  学刊,2020,38(10):10-15,260-261.
              sion  of  inflammasomes  during  viral  and  microbial  infec‐  [21]  ZOU Y C,MA P,LI B,et al. Traditional Chinese medi‐
              tion[J]. Cell Mol Life Sci,2025,82(1):56.           cine for the treatment of chronic inflammatory diseases:a
          [ 9 ]  HUANG  Q,SHAN  Q,MA  F T,et  al.  Chlorogenic  acid   review  of  inhibitors  for  NLRP3  inflammasome[J].  Adv
              mitigates heat stress-induced oxidative damage in bovine   Chin Med,2025,2(1):1-12.


          中国药房  2025年第36卷第18期                                              China Pharmacy  2025 Vol. 36  No. 18    · 2339 ·
   124   125   126   127   128   129   130   131   132   133   134